الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
Summary
The most common cancer among women worldwide is breast cancer, which causes 14% of all cancer-related deaths .Major treatment progress has been achieved over the past 30 years, leading to improved survival. Systemic and radiation therapies have experienced dramatic paradigm changes in the past 2 decades, and surgical techniques have been refined as well. Oncoplastic breast surgery (OPS) has been developed to improve cosmetic outcomes after breast cancer surgery.
Neoadjuvant chemotherapy (NAC) has traditionally been the standard approach in patients with locally advanced and inflammatory breast cancer, allowing for a reduction in disease volume and therefore optimizing surgical resection of the disease in the breast. This has evolved to now also include NAC in patients with large operable cancers who desire breast conservation and patients with early stage breast cancer, especially HER-2 positive and triple negative tumors.
The optimal timing of systemic therapy in breast cancer has long been studied and debated. Several large randomized clinical trials have demonstrated no significant difference in disease-free and overall survival between patients receiving chemotherapy in the neoadjuvant and the adjuvant setting .The most striking advantage of NAC identified by these trials is an increase in the rate of breast conserving surgery.
The neoadjuvant approach has several advantages, including potentially rendering inoperable breast cancer operable, providing the ability to assess a tumor’s response to systemic treatment, and increasing surgical options. This may be beneficial in terms of post-operative complications, cosmetic outcomes, and resource utilization.In addition, pathologic complete response (pCR) has been shown in a pooled analysis and a meta-analysis to be an excellent prognostic marker for long term outcomes.
No recommendation regarding the most effective time interval between neoadjuvant chemotherapy and surgery has yet been made.
Reported clinical trials in the neoadjuvant setting have varying time intervals between the completion of chemotherapy and surgery ranging between 1 and 5 weeks from last dose of NAC
The main results of the study revealed that:
mean of time interval were 3.66 with range from 2 to 7 weeks
All of patients were on Neoadjevant Chemotherapy.
153 patients (61.2%) were subjected to and 97 patients (38.8%) were subjected to CBS
8 patients (3.2%) had reoperation due to complications.
2 patients (0.8%) had infection, 2 patients (0.8%) had wound Healing issues and 4 patients (1.6%) had seroma need Evacuation surgically.
250 patients (100%) have no recurrence and 250 patients (100%) were alive to end of study and All Cases take post-operative chemotherapy.
There were no statistically significant difference betweentime of interval among surgery and reoperation due to complications.
Recurrence and Survival were not applicable
there were statistically significant increase age at patients did operation before 4 weeks.